Powered by
Oramed to Present at Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference on March 28, 2017

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP)(http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Dr. Miriam Kidron, Oramed's Chief Scientific Officer, will deliver a presentation titled, "Oral Insulin for Diabetes Treatment: Bypassing the Roadblock," at the upcomingCambridge Healthtech Institute's Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference in Cambridge, Massachusetts.   

Dr. K

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 5 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox